Aimovig, erenumab-aooe
Named-patient access overview. Aimovig is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions.
About Aimovig
Aimovig is the brand name for erenumab-aooe, a fully human monoclonal antibody developed and co-commercialized by Amgen and Novartis. The US Food and Drug Administration approved Aimovig in May 2018 as the first preventive treatment for migraine designed specifically around the calcitonin gene-related peptide pathway. It is a once-monthly subcutaneous injection delivered through a single-use autoinjector pen.
Aimovig is part of the anti-CGRP class of preventive migraine therapies, which arrived in clinic after decades in which migraine prevention relied on repurposed antihypertensives, antidepressants, and antiepileptics that were never designed for the indication. For patients who have cycled through 2 or more of those older preventives without adequate response, an anti-CGRP option is often the next clinical step.
Mechanism of action
Calcitonin gene-related peptide, or CGRP, is a small protein released during a migraine attack. It dilates blood vessels in the meninges and amplifies pain signaling. Erenumab is engineered to bind the CGRP receptor on the surface of nerve cells, blocking CGRP from docking and triggering the downstream cascade that produces a migraine. Unlike the other approved anti-CGRP antibodies (which bind the CGRP ligand itself), Aimovig is the only one in its class that binds the receptor.
In plain terms: the medicine sits on the doorknob that CGRP would otherwise turn, and refuses to let it open the door.
FDA-approved indications
Aimovig is approved by the FDA for the preventive treatment of migraine in adults. The approved label covers both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, with at least 8 of them being migraine days). It is not approved as an acute treatment, meaning it is not taken to stop an attack already in progress. It is taken on a fixed monthly schedule whether or not a migraine is occurring.
Dosing and administration
The standard starting dose is 70 mg administered subcutaneously once every month. Some patients may benefit from 140 mg once monthly, delivered as either a single 140 mg autoinjector or as two consecutive 70 mg injections. The autoinjector is designed for self-injection at home into the thigh, abdomen, or upper arm after a brief training session. Aimovig must be stored refrigerated between 36 and 46 degrees Fahrenheit and protected from light. It can sit at room temperature for up to 7 days before use if needed, but cannot be returned to the refrigerator afterward.
Side-effect profile
The most commonly reported side effects in clinical trials and post-marketing surveillance are injection-site reactions (redness, mild pain, or itching at the injection point) and constipation. Constipation is worth flagging because in a small subset of patients it can be severe and, in rare cases, has been associated with hospitalization or surgical intervention. Patients with a history of chronic constipation should discuss this with their physician before starting.
Other reported effects include muscle spasms, hypersensitivity reactions, and (rarely) an increase in blood pressure. Aimovig should not be used in patients with known serious hypersensitivity to erenumab or to any of the excipients. As with any biologic, the long-term safety profile continues to be characterized in ongoing post-marketing studies.
Why international patients seek Aimovig cross-border
In several countries served by Reserve Meds, Aimovig is either not yet locally registered, not consistently available, or available only under restrictive payer or formulary criteria that exclude patients who would clearly benefit. Migraine is also significantly under-treated in many of these markets, with most patients still managed on older oral preventives even when those have failed. Named-patient programs and personal-import pathways exist precisely for cases like these: a patient with a clear clinical indication, a treating physician's prescription, and no reasonable access route at home.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserve Meds sources Aimovig from DSCSA-compliant US specialty wholesalers, with full serialization and an unbroken cold chain from US warehouse to destination. We do not handle controlled substances. We do not sell direct to consumers. Every Aimovig case is physician-led, documented, and routed through the destination country's lawful import framework.
Start a request for Aimovig
Submit a 60-second intake. Our clinical team will review your case and respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote.
Access by country
Reserve Meds publishes a detailed country deep-dive for Aimovig in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Frequently asked questions
How can I get Aimovig if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Aimovig for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Aimovig through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Aimovig. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Aimovig through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Aimovig to a patient?
Reserve Meds sources Aimovig from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Aimovig cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Aimovig?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.